Table 3.
Patient characteristics by dose
| Characteristic | Value |
|---|---|
| UICC seventh stage, n | |
| ● 60–66 GyRBE/30–33 Fr | 37 |
| IIIA:IIIB | 19:20 |
| T-stage, n | |
| X:0:1:2:3:4 | 1:2:10:12:5:7 |
| N-stage, n | |
| 0:1:2:3 | 2:1:17:17 |
| Primary site, n | |
| Upper:middle:lower:others | 17:3:15:2 |
| Central:peripheral:others | 10:26:1 |
| ● 70–74 GyRBE/33–37 Fr | 37 |
| IIIA:IIIB | 16:21 |
| T-stage, n | |
| 0:1:2:3:4 | 0:5:10:10:12 |
| N-stage, n | |
| 0:1:2:3 | 3:5:11:18 |
| Primary site, n | |
| Upper:middle:lower:others | 24:2:11:0 |
| Central:peripheral:others | 12:25:0 |
Fr, fraction, UICC, Union for International Cancer Control [25].